Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome

IF 13.4 1区 医学 Q1 HEMATOLOGY
Alexandre Bazinet, Guillermo Montalban-Bravo, Alex Bataller, Danielle Hammond, Sanam Loghavi, Kelly Chien, Koji Sasaki, Ian Bouligny, Mahesh Swaminathan, Wei Ying Jen, Uday Popat, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Nicholas Short, Naval Daver, Farhad Ravandi, Guillermo Garcia-Manero
{"title":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome","authors":"Alexandre Bazinet, Guillermo Montalban-Bravo, Alex Bataller, Danielle Hammond, Sanam Loghavi, Kelly Chien, Koji Sasaki, Ian Bouligny, Mahesh Swaminathan, Wei Ying Jen, Uday Popat, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Nicholas Short, Naval Daver, Farhad Ravandi, Guillermo Garcia-Manero","doi":"10.1038/s41375-025-02760-x","DOIUrl":null,"url":null,"abstract":"<p><b>TO THE EDITOR</b>:</p><p>Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) neoplasms that arise through a stepwise evolutionary process due to the expansion of clonal HSCs [1, 2]. The Revised International Prognostic Scoring System (IPSS-R), based on clinical and pathologic characteristics, has long been the standard risk stratification system used in clinical trials and practice [3]. Recent efforts have integrated genomic data within the Molecular International Prognostic Scoring System (IPSS-M) [4]. Compared to the IPSS-R, the IPSS-M results in a change in risk category in a significant number of patients, with major clinical implications. Indeed, the classification of a patient as either higher risk (HR) or lower risk (LR) is fundamental in the management of MDS, with widely differing treatment approaches. In this study, we evaluated a large cohort of patients with MDS and compared the characteristics and clinical behavior of patients who experienced a change in overall risk (HR versus LR) when re-stratified from IPSS-R to IPSS-M.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"34 1","pages":""},"PeriodicalIF":13.4000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41375-025-02760-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

TO THE EDITOR:

Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) neoplasms that arise through a stepwise evolutionary process due to the expansion of clonal HSCs [1, 2]. The Revised International Prognostic Scoring System (IPSS-R), based on clinical and pathologic characteristics, has long been the standard risk stratification system used in clinical trials and practice [3]. Recent efforts have integrated genomic data within the Molecular International Prognostic Scoring System (IPSS-M) [4]. Compared to the IPSS-R, the IPSS-M results in a change in risk category in a significant number of patients, with major clinical implications. Indeed, the classification of a patient as either higher risk (HR) or lower risk (LR) is fundamental in the management of MDS, with widely differing treatment approaches. In this study, we evaluated a large cohort of patients with MDS and compared the characteristics and clinical behavior of patients who experienced a change in overall risk (HR versus LR) when re-stratified from IPSS-R to IPSS-M.

Abstract Image

不一致的修订与分子国际预后评分系统对骨髓增生异常综合征风险的影响
致编辑:骨髓增生异常综合征(MDS)是一种造血干细胞(HSC)肿瘤,由于克隆造血干细胞的扩增而通过逐步进化过程产生[1,2]。修订后的国际预后评分系统(IPSS-R)基于临床和病理特征,长期以来一直是临床试验和实践中使用的标准风险分层系统。最近的工作是将基因组数据整合到分子国际预后评分系统(IPSS-M)[4]中。与IPSS-R相比,IPSS-M导致大量患者的风险类别发生变化,具有重要的临床意义。事实上,将患者分为高风险(HR)或低风险(LR)是MDS管理的基础,治疗方法存在很大差异。在这项研究中,我们评估了一大群MDS患者,并比较了从IPSS-R重新分层到IPSS-M时总体风险(HR vs LR)发生变化的患者的特征和临床行为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia
Leukemia 医学-血液学
CiteScore
18.10
自引率
3.50%
发文量
270
审稿时长
3-6 weeks
期刊介绍: Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信